文档介绍：中国感染与化疗杂志 2022 年 5 月 20 日第 22 卷第 3 期 2022 22 3 307
eases, concomitant medications, piperacillin-tazobactam treatment
duration, and onset time and outcome of neutropenia were statistically analyzed. Naranjo adverse drug reactions probability scale was
used to assess the causality of its adverse reactions. Results A total of 22 cases of piperacillin-tazobactam-induced neutropenia were
identified, including 12 males and 10 females. The average age was years. Half of the patients (11 cases) received piperacillin-
tazobactam to treat pulmonary infections. Fifteen patients received the recommended dosing regimen of g, q8h. The average
treatment duration was days. The average cumulative dose was g. The causality of piperacillin-tazobactam-induced
neutropenia was “definite” in 5 cases, “probable” in 15 cases, and “possible” in 2 cases according to Naranjo scale. The onset time
of neutropenia was 3-28 days after initiation of piperacillin-tazobactam treatment. Fourteen patients developed neutropenia after
piperacillin-tazobactam treatment for at least 15 days. The absolute neutrophil count was less than ×10 9/L in 10 patients. The
neutrophil count returned to normal in all cases about 7 days after discontinuing piperacillin-tazobactam or symptomatic treatment.